(1 - 16 from 20
)
Sofosbuvir + simeprevir dual therapy shows high cure rates for...
www.aidsmap.com
Mark Sulkowski of Johns Hopkins presented findings from a sub-analysis of cohort 1, looking at the effect of predictive factors including HCV subtype 1a vs 1b ...
2018 Annual CCO Hepatitis Symposium: Regional Workshops in New York,...
events.clinicaloptions.com
8:30 AM Interactive Plenary: Simplified HCV Therapy in Faculty: David R. Nelson, MD. 9:00 AM Interactive Plenary: Special HCV Populations in Faculty: Mark Sulkowski, MD. 9:30 AM Question and Answer Session. 10:00 AM Interactive Roundtable: Current Controversies in Viral Hepatitis Moderator: Paul Martin ...
3D regimen plus ribavirin yields high SVR in patients with HIV/HCV
www.healio.com
In the TURQUOISE-1 pilot study, a majority of patients coinfected with hepatitis C virus infection genotype 1 and HIV-1 achieved sustained virologic response...
Harvoni safe, effective for HCV–infected patients with sickle cell...
www.healio.com
Mark Sulkowski. Mark S. Sulkowski. itj+ Search. Researchers evaluated the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF; Gilead Sciences) in patients with sickle cell disease — a population that until recently may have been ineligible for HCV treatment. In this open-label, single-center study, they ...
sorted by relevance / date